Stock Traders Buy High Volume of Corbus Pharmaceuticals Put Options (NASDAQ:CRBP)

Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) saw some unusual options trading activity on Tuesday. Traders acquired 10,124 put options on the stock. This is an increase of 690% compared to the typical volume of 1,282 put options.

Analysts Set New Price Targets

Several equities research analysts recently weighed in on CRBP shares. Weiss Ratings restated a “sell (d-)” rating on shares of Corbus Pharmaceuticals in a research report on Friday, July 17th. Wedbush decreased their price objective on Corbus Pharmaceuticals from $38.00 to $30.00 and set an “outperform” rating on the stock in a research report on Wednesday, May 27th. Mizuho set a $33.00 price target on shares of Corbus Pharmaceuticals in a research note on Thursday, August 13th. Guggenheim reissued a “buy” rating on shares of Corbus Pharmaceuticals in a research note on Tuesday, May 26th. Finally, HC Wainwright restated a “buy” rating and set a $35.00 price objective on shares of Corbus Pharmaceuticals in a report on Monday. Eight equities research analysts have rated the stock with a Buy rating and two have issued a Sell rating to the company. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $41.00.

Key Stories Impacting Corbus Pharmaceuticals

Here are the key news stories impacting Corbus Pharmaceuticals this week:

• Positive Sentiment: Promising CRB-913 obesity data: Corbus reported statistically significant and clinically meaningful average weight loss of 5% after 12 weeks at the 60-mg dose in the Phase 1b CANYON-1 trial. No weight-loss plateau was observed, and the oral, non-incretin treatment showed generally favorable gastrointestinal tolerability. Corbus Pharmaceuticals Announces Positive Topline Data from CANYON-1 Study
• Positive Sentiment: Potential differentiation from GLP-1 drugs: Psychiatric adverse events were broadly in line with GLP-1 medicines, while the emerging gastrointestinal safety profile could support CRB-913’s positioning as an oral alternative in the obesity market. The data will be presented as a late-breaking disclosure at ObesityWeek 2026. Corbus Pharmaceuticals Obesity Drug Avoids Depressive Effects
• Positive Sentiment: Analyst support: HC Wainwright reaffirmed its Buy rating and maintained a $35 price target, implying substantial upside if CRB-913 continues to deliver positive clinical results.
• Positive Sentiment: Heavy call buying: Investors purchased 7,228 call options on Monday, roughly 523% above typical daily volume, indicating elevated speculative interest in a potential rebound or additional favorable news.
• Neutral Sentiment: Further investor interpretation: A transcript discussing the Phase 1b results and CRB-913’s potential as a weight-loss therapy may provide additional details, but the study remains early-stage and requires further clinical validation. CRB-913 Phase 1b Topline Results Transcript
• Negative Sentiment: Unusually high put activity: Investors purchased 10,124 put options Tuesday, approximately 690% above normal volume. This bearish hedging or speculative activity may be contributing to pressure on CRBP despite the positive trial announcement.

Insider Buying and Selling at Corbus Pharmaceuticals

In other Corbus Pharmaceuticals news, CEO Yuval Cohen sold 17,000 shares of Corbus Pharmaceuticals stock in a transaction that occurred on Friday, August 7th. The stock was sold at an average price of $10.08, for a total value of $171,360.00. Following the sale, the chief executive officer owned 157,316 shares of the company’s stock, valued at $1,585,745.28. The trade was a 9.75% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, CFO Sean F. Moran sold 12,000 shares of the company’s stock in a transaction that occurred on Friday, August 7th. The stock was sold at an average price of $10.08, for a total value of $120,960.00. Following the sale, the chief financial officer directly owned 84,694 shares in the company, valued at $853,715.52. This trade represents a 12.41% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. 3.50% of the stock is currently owned by insiders.

Institutional Investors Weigh In On Corbus Pharmaceuticals

Hedge funds have recently added to or reduced their stakes in the business. Pale Fire Capital SE grew its holdings in Corbus Pharmaceuticals by 14.5% during the 1st quarter. Pale Fire Capital SE now owns 21,350 shares of the biopharmaceutical company’s stock worth $200,000 after acquiring an additional 2,700 shares in the last quarter. Royal Bank of Canada boosted its holdings in Corbus Pharmaceuticals by 81.2% during the first quarter. Royal Bank of Canada now owns 29,901 shares of the biopharmaceutical company’s stock worth $281,000 after buying an additional 13,401 shares in the last quarter. Bank of America Corp DE grew its holdings in Corbus Pharmaceuticals by 53,592.3% in the first quarter. Bank of America Corp DE now owns 13,960 shares of the biopharmaceutical company’s stock valued at $131,000 after purchasing an additional 13,934 shares during the last quarter. Engineers Gate Manager LP increased its stake in shares of Corbus Pharmaceuticals by 109.9% during the 2nd quarter. Engineers Gate Manager LP now owns 29,800 shares of the biopharmaceutical company’s stock worth $280,000 after purchasing an additional 15,600 shares in the last quarter. Finally, Seven Fleet Capital Management LP boosted its position in Corbus Pharmaceuticals by 51.0% during the first quarter. Seven Fleet Capital Management LP now owns 85,687 shares of the biopharmaceutical company’s stock worth $805,000 after acquiring an additional 28,937 shares during the last quarter. 64.64% of the stock is currently owned by institutional investors and hedge funds.

Corbus Pharmaceuticals Stock Down 17.3%

Shares of Corbus Pharmaceuticals stock traded down $1.40 during mid-day trading on Tuesday, reaching $6.68. 2,830,192 shares of the stock traded hands, compared to its average volume of 435,593. Corbus Pharmaceuticals has a fifty-two week low of $6.32 and a fifty-two week high of $20.56. The stock has a market capitalization of $124.73 million, a PE ratio of -1.08 and a beta of 2.63. The business has a 50-day moving average of $9.75 and a 200 day moving average of $9.45.

Corbus Pharmaceuticals (NASDAQ:CRBP) last posted its quarterly earnings results on Thursday, August 6th. The biopharmaceutical company reported ($1.81) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.26) by ($0.55). On average, equities research analysts expect that Corbus Pharmaceuticals will post -5.62 EPS for the current fiscal year.

About Corbus Pharmaceuticals

Corbus Pharmaceuticals Holdings, Inc is a clinical-stage biopharmaceutical company dedicated to the development and commercialization of therapeutic candidates for rare, life-threatening inflammatory and fibrotic diseases. The company’s lead investigational therapy, lenabasum, is a synthetic, oral cannabinoid receptor type 2 (CB2) agonist designed to resolve chronic inflammation by harnessing the body’s innate resolution pathways. Corbus operates by advancing small-molecule compounds through preclinical and clinical studies to address unmet medical needs in autoimmune and inflammatory disorders.

Lenabasum is currently under evaluation in a Phase 3 clinical trial for diffuse cutaneous systemic sclerosis (dcSSc) and in a Phase 2 study for cystic fibrosis–related inflammation.